FONDATION-IPSEN
The Fondation IPSEN Longevity Prize will be given this year at the GSA meeting (Gerontological Society of America), in New Orleans on November 19th, 2016. The international jury chaired by Professor Thomas Kirkwood (Newcastle University, UK and Copenhagen University, Denmark), have unanimously decided to award the prize to Kaare Christensen for his pioneering work on the importance of genes and environment in aging and longevity.
Kaare Christensen, MD, PhD, DRMSC, is Professor of Epidemiology at the University of Southern Denmark and Senior Research Scientist at the Terry Sanford Institute, Duke University, North Carolina, USA. Dr. Christensen is the Director of the Danish Twin Registry and the Danish Aging Research Center. He has conducted a long series of studies among twins and the oldest-old in order to shed light on the importance of genes and environment in aging and longevity. Furthermore, he has a longstanding interest in the relation between early life events and later life health outcome.
Abstract of his lecture: “Is Mortality written on the face? Or Elsewhere?”
Predicting length of life is of interest to individuals, medical doctors, demographers and researchers on aging. While most people would probably be uncomfortable with an exact prediction at an individual level (if that were possible), the identification of factors associated with health and survival can potentially provide the basis for decision making, interventions and public health initiatives. A series of “the usual suspects” is known to be associated with health and survival, e.g. birth cohort, gender, smoking and other life style factors, genetics, early life and socioeconomic factors. Over the last decades, this list has been extended with biomarkers of aging that include performance measures and molecular markers such as leukocyte telomere length and DNA methylation age. We have used nationwide cohort studies of twins, oldest-old individuals and long-lived families in Denmark to understand variance in health and survival and to identify clinically useful biomarkers of aging. Perhaps surprisingly, we have found that among the elderly, simple, low-tech biomarkers, including perceived age based on photos, are among the most powerful indicators of aging.
The Longevity Prize
Created in 1996, this Prize of the Fondation Ipsen has been awarded every year to renowned specialists in Longevity:
Caleb E. Finch (University of Southern California, Los Angeles, USA), Vaïno Kannisto (Odense University, Denmark) , Roy L. Walford (formerly University of California Los Angeles, USA), John E. Morley (St. Louis University, USA), Paul B. and Margret M. Baltes (formerly Free University of Berlin, Germany), Justin D. Congdon (University of Georgia, Aiken, USA), George M. Martin (University of Washington, Seattle, USA), James W. Vaupel (Max-Planck Institute for Demographic Research, Rostock, Germany), Linda Partridge (University College London, UK), Sir Michael Marmot (University College London, UK), Cynthia Kenyon (University of California, San Francisco, USA), David J.P. Barker (University of Southampton, UK), Gerald McClearn (Pennsylvania State University, University Park, USA), Jacques Vallin (French National Institute of Demography, Paris, France), Judith Campisi (Buck Institute for Age Research, Novato, USA), Thomas Kirkwood (Newcastle University, Newcastle upon Tyne, UK), Linda Fried (Columbia University, New York, USA), Gary Ruvkun (Harvard Medical School - CCIB, Boston, US), Luigi Ferrucci (National Institute on Aging, NIH, Baltimore, USA) and Steven N. Austad (University of Alabama at Birmingham, USA).
Members of the jury
Thomas Kirkwood, President (Newcastle University, UK Copenhagen University, Denmark), Judith Campisi (Buck Institute for Research on Aging, Novato, USA), Eileen Crimmins (University of Southern California, Los Angeles, USA), Caleb Finch (University of Southern California, Los Angeles, USA), Bernard Jeune* (University of Southern Denmark, Odense, Denmark), George Martin* (University of Washington, Seattle, USA), Yasuyuki Gondo (Osaka University, Japan), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France), Bruno Vellas (University of Toulouse, France), Marja Jylhä (University of Tampere, Finland), Steven N. Austad (University of Alabama at Birmingham, USA), Luigi Ferrucci (National Institute on Aging, Baltimore, USA) and a Fondation IPSEN representative.
(* Former Jury Members).
The Fondation IPSEN
Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the science journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161119005007/en/
Contact:
Image Sept
Isabelle de Segonzac, +33 (0)1 53 70 74 70
isegonzac@image7.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enerin raises €15 million Series A to industrialise modular high-temperature heat pumps for global industry26.11.2025 10:00:00 CET | Press release
Norway-based technology leader in industrial heat pumps, Enerin AS, has raised €15 million in an oversubscribed Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy. The investment marks Enerin’s transition from technology pioneer to serial production. Proceeds will expand commercial and manufacturing operations, and accelerate next-generation development. Johnson Controls’ participation provides strategic validation and global reach from one of the world’s leading providers of energy systems. Enerin, a technology leader in high-temperature heat pumps, has raised €15 million (NOK 180 million) in a Series A led by Climentum Capital, The Footprint Firm, Johnson Controls and Move Energy, with participation from PSV Hafnium and Momentum. “This investment marks our shift from pioneering to full industrialisation, bringing proven high-temperature technology from Norway to industries worldwide,” said Arne Høeg, Founder and CEO of Enerin. “Industrial companie
IQM to Invest Over €40 Million to Expand Finland Production Facility, Accelerate Innovation and Fuel Growth26.11.2025 09:49:00 CET | Press release
The new facility will produce advanced quantum chips for error corrected quantum computers, almost double the cleanroom space and system assembly line capacity to produce up to 30 quantum computers per year. The integrated quantum computer production line will be one of the world’s most advanced of its kind combining fabrication of quantum chips and system assembly. The expansion is expected to be completed by the first quarter of 2026. The expansion is part of IQM’s long-term commitment to scale its infrastructure and execute the ambitious technology roadmap aiming at 1M quantum computers by 2033. IQM Quantum Computers, a global leader in superconducting quantum computers, today announced over €40 million investment to expand its state-of-the-art production facility in Finland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126943986/en/ This strategic expansion will accelerate the development, fabrication and testing of
Thredd Powers Successful Migration of BigPay’s Card Portfolio to Next-Gen Platform26.11.2025 09:00:00 CET | Press release
The transition of millions of cards showcases Thredd’s superior capabilities amid a high-stakes, global trend of sunsetting legacy processing engagements Thredd, the leading next-generation global payments processor, has successfully migrated BigPay’s virtual and physical card portfolio from its previous, legacy processor to Thredd’s next-generation platform, underscoring Thredd’s leadership in complex card portfolio migrations. The migration project, one of several in recent years, included over 2.5 million cards and highlights Thredd’s unique combination of deep migration experience, robust processes, and advanced technology—qualities increasingly critical as the industry faces a wave of modernisation and replatforming. This achievement comes at a pivotal moment for the industry. Industry analysts estimate that retail banks failing to modernise could see 10% to 15% of their payments revenue at risk annually as legacy platforms struggle to keep pace with demands for hyperpersonalizati
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 08:00:00 CET | Press release
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 01:00:00 CET | Press release
Venture Global’s fourth long-term contract with a Japanese company7.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
